We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
- Authors
Yang, Yingzhu; Du, Nannan; Xie, Laidi; Jiang, Jing; Mo, Jiahang; Hong, Jiaze; Mao, Danyi; Ng, Derry Minyao; Shi, Huiwei
- Abstract
Background: The purpose of this study was to explore the efficacy and tolerability of poly ADP-ribose polymerase (PARP) inhibitors in patients with ovarian cancer. Methods: The meta-analysis searched the PubMed, Web of Science, EBSCO, and Cochrane libraries from inception to February 2020 to identify relevant studies. And the main results of this study were long-term prognosis and treatment-related adverse events. Results: The results showed that the addition of PARP inhibitors could significantly prolong progression-free survival (PFS) and overall survival (OS) for patients with ovarian cancer (HR 0.44, 95% CI 0.34–0.53, p < 0.001; HR, 0.79, 95% CI 0.65–0.94, p < 0.001, respectively). In the BRCA 1/2 mutation patients, the HR of PFS was 0.29 (p < 0.001), and the HR was 0.51 (p < 0.001) in the no BRCA 1/2 mutation patients. The HR of PFS was 0.40 (p < 0.001) in the homologous recombination deficiency (HRD) mutation patients, while the HR was 0.80 (p < 0.001) in the no HRD mutation patients. Moreover, the analysis found that the use of PARP inhibitors did not significantly increase the risk of all grade adverse events (AEs) (RR = 1.04, p = 0.16). But the incidence of grade 3 or higher AEs was increased (RR = 1.87, p = 0.002). In general, the AEs were mainly manifested in the blood system. Conclusions: PARP inhibitors can improve the prognosis of ovarian cancer patients with and without genetic mutations (BRCA 1/2 or HRD). Furthermore, PARP inhibitors were tolerable to patients when added to their current therapy, although it inevitably adds the grade 3 and higher AEs.
- Subjects
POLY(ADP-ribose) polymerase; OVARIAN cancer; POLY ADP ribose; META-analysis; BRCA genes; CANCER treatment
- Publication
World Journal of Surgical Oncology, 2020, Vol 18, Issue 1, p1
- ISSN
1477-7819
- Publication type
Article
- DOI
10.1186/s12957-020-01931-7